NG
NVO

Novem Group’s Novo Nordisk NVO Stock Holding History

Novem Group’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,000
Closed -$1.29M – 394
2024
Q4 		$1.29M Buy
+15,000
New +$1.62M 0.19% 96

Other funds holding NVO

SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
QI
QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
OFA
Oak Family Advisors Chicago, Illinois $391M AUM 26.35% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

Novem Group's NVO Position: Q2 2026 in Review

Novem Group sold out of Novo Nordisk (NVO) in Q2 2026, closing a stake of 20,869 shares — an estimated $767K sold.

Novem Group first reported a position in NVO in Q4 2024 and held it in 3 quarters. The position peaked at $1.01M in Q4 2025. 389 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Novem Group reported no remaining Novo Nordisk position as of Q2 2026 after selling out during the quarter.
  • Novem Group sold 20,869 Novo Nordisk shares in Q2 2026, an estimated $767K.
  • Novem Group first reported a position in Novo Nordisk in Q4 2024 and held it in 3 quarters.
  • Novem Group's Novo Nordisk position peaked at $1.01M in Q4 2025.
  • 389 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Novem Group's 13F filing for Q2 2026, filed 21 Jul 2026.